Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics

Drug Metabolism and Disposition

Volumn 42, Issue 7, 2014, Pages 1174-1179

  Kim, AnHye ^a   Chung, Inbum ^a   Yoon, Seo Hyun ^a   Yu, Kyung Sang ^a   Lim, Kyoung Soo ^a   Cho, Joo Youn ^a   Lee, Howard ^a   Jang, In Jin ^a   Chung, Jae Yong ^b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; METFORMIN; PANTOPRAZOLE; RABEPRAZOLE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PROTON PUMP INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; DRUG INTERACTION; METABOLISM;

AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PROTON PUMP INHIBITORS;

EID: 84903141985     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055616     Document Type: Article

References (29)

1. Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, Sanz-Paris A, Trincado-Aznar P, and Albero-Gamboa R (2011) Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2:217-220.
2. Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ, and Ware JA (2012) Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 92:203-213.
3. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, and Horowitz M (2001) Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 161:1989-1996.
4. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, and Horowitz M (2002) GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol 97:604-611.
5. Chen Y, Li S, Brown C, Cheatham S, Castro RA, Leabman MK, Urban TJ, Chen L, Yee SW, and Choi JH, et al. (2009) Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 19:497-504.
6. Crouch MA, Mefford IN, and Wade EU (2012) Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J Am Board Fam Med 25:50-54.
7. Desai D, Wong B, Huang Y, Tang D, Hemenway J, Paruchuri S, Guo H, Hsieh D, and Timmins P (2014) Influence of dissolution media pH and USP1 basket speed on erosion and disintegration characteristics of immediate release metformin hydrochloride tablets. Pharm Dev Technol 2014:12 Epub ahead of print.
8. Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, and Drozdzik M (2012) CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol 68:1267-1274.
9. Gong L, Goswami S, Giacomini KM, Altman RB, and Klein TE (2012) Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 22:820-827.
10. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, and Kirkpatrick CM, et al. (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81-98.
11. Hershcovici T, Jha LK, Gadam R, Cui H, Gerson L, Thomson S, and Fass R (2012) The relationship between type 2 diabetes mellitus and failure to proton pump inhibitor treatment in gastroesophageal reflux disease. J Clin Gastroenterol 46:662-668.
12. Higgins JW, Bedwell DW, and Zamek-Gliszczynski MJ (2012) Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos 40:1170-1177.
13. Hove KD, Brøns C, Færch K, Lund SS, Petersen JS, Karlsen AE, Rossing P, Rehfeld JF, and Vaag A (2013) Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia 56: 22-30.
14. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
15. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, and Kato M, et al. (2002) Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4:E25.
16. Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, and Sugiyama Y (2012) Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340:393-403.
17. Kirpichnikov D, McFarlane SI, and Sowers JR (2002) Metformin: an update. Ann Intern Med 137:25-33.
18. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, and Schwab M (2011) Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS ONE 6:e22163.
19. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Sato T, Haruna Y, Miyamoto T, Kanda T, Kawano S, and Hori M (2004) Gastroesophageal reflux disease related to diabetes: Analysis of 241 cases with type 2 diabetes mellitus. J Gastroenterol Hepatol 19:258-265.
20. Padwal RS, Gabr RQ, Sharma AM, Langkaas LA, Birch DW, Karmali S, and Brocks DR (2011) Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 34:1295-1300.
21. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, and Karam JH (1996) Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 36:1012-1021.
22. Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, and Lewin A (2006) Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 29:759-764.
23. Sellin JH and Chang EB (2008) Therapy Insight: gastrointestinal complications of diabetes - pathophysiology and management. Nat Clin Pract Gastroenterol Hepatol 5:162-171.
24. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, and Brett CM, et al. (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 83:273-280.
25. Song IS, Shin HJ, Shim EJ, Jung IS, Kim WY, Shon JH, and Shin JG (2008) Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 84:559-562.
26. Stedman CA and Barclay ML (2000) Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14:963-978.
27. Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, and Giacomini KM (2013) Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem 56:781-795.
28. Yang JC, Yang YF, Uang YS, Lin CJ, and Wang TH (2009) Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol 67:503-510.
29. Zhou M, Xia L, and Wang J (2007) Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 35:1956-1962.